P53 and p16INK4A independent induction of senescence by chromatin-dependent alteration of S-phase progression

Nature Communications

Volumn 2, Issue 1, 2011, Pages

  Prieur, Alexandre ^a   Besnard, Emilie ^a   Babled, Amélie ^a   Lemaitre, Jean Marc ^a,b  

^a INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^b CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; HISTONE ACETYLTRANSFERASE PCAF; PROTEIN P53; TP53 PROTEIN, HUMAN;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CHROMATIN; CONTROLLED STUDY; DNA DAMAGE; DNA REPLICATION TIMING; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; SENESCENCE; ACETYLATION; CELL AGING; CELL LINE; DNA REPLICATION; FLOW CYTOMETRY; PHYSIOLOGY;

ACETYLATION; CELL AGING; CELL LINE; CHROMATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA DAMAGE; DNA REPLICATION; FLOW CYTOMETRY; HUMANS; S PHASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80053391506     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms1473     Document Type: Article

References (48)

1. Prieur, A. & Peeper, D. S. Cellular senescence in vivo: A barrier to tumorigenesis. Curr. Opin. Cell Biol. 20, 150-155 (2008).
2. Campisi, J. & d'Adda di Fagagna, F. Cellular senescence: When bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 8, 729-740 (2007). (Pubitemid 47312822)
3. Bartkova, J. et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633-637 (2006). (Pubitemid 44864442)
4. Di Micco, R. et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444, 638-642 (2006). (Pubitemid 44864443)
5. Narita, M. et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113, 703-716 (2003). (Pubitemid 36724935)
6. Narita, M. et al. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 126, 503-514 (2006). (Pubitemid 44163608)
7. Zhang, R., Chen, W. & Adams, P. D. Molecular dissection of formation of senescence-associated heterochromatin foci. Mol. Cell. Biol. 27, 2343-2358 (2007). (Pubitemid 46418486)
8. Kalkhoven, E. CBP and p300: HATs for different occasions. Biochem. Pharmacol. 68, 1145-1155 (2004). (Pubitemid 39094280)
9. Wang, L., Tang, Y., Cole, P. A. & Marmorstein, R. Structure and chemistry of the p300/CBP and Rtt109 histone acetyltransferases: Implications for histone acetyltransferase evolution and function. Curr. Opin. Struct. Biol. 18, 741-747 (2008).
10. Balasubramanyam, K. et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem. 279, 51163-51171 (2004). (Pubitemid 40017859)
11. Bowers, E. M. et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: Identification of a selective small molecule inhibitor. Chem. Biol. 17, 471-482 (2010).
12. Blow, J. J. & Ge, X. Q. A model for DNA replication showing how dormant origins safeguard against replication fork failure. EMBO Rep. 10, 406-412 (2009).
13. Maya-Mendoza, A., Petermann, E., Gillespie, D. A., Caldecott, K. W. & Jackson, D. A. Chk1 regulates the density of active replication origins during the vertebrate S phase. EMBO J. 26, 2719-2731 (2007). (Pubitemid 46884282)
14. Lande-Diner, L., Zhang, J. & Cedar, H. Shifts in replication timing actively affect histone acetylation during nucleosome reassembly. Mol. Cell 34, 767-774 (2009).
15. Vogelauer, M., Rubbi, L., Lucas, I., Brewer, B. J. & Grunstein, M. Histone acetylation regulates the time of replication origin firing. Mol. Cell 10, 1223-1233 (2002). (Pubitemid 35453838)
16. Branzei, D. & Foiani, M. The checkpoint response to replication stress. DNA Repair 8, 1038-1046 (2009).
17. Jackson, S. P. & Bartek, J. The DNA-damage response in human biology and disease. Nature 461, 1071-1078 (2009).
18. Chen, C. C. et al. Acetylated lysine 56 on histone H3 drives chromatin assembly after repair and signals for the completion of repair. Cell 134, 231-243 (2008).
19. Das, H. et al. Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. Proc. Natl Acad. Sci. USA 103, 6653-6658 (2006).
20. Li, Q. et al. Acetylation of histone H3 lysine 56 regulates replication-coupled nucleosome assembly. Cell 134, 244-255 (2008). (Pubitemid 352010333)
21. Tjeertes, J. V., Miller, K. M. & Jackson, S. P. Screen for DNA-damage-responsive histone modifications identifies H3K9Ac and H3K56Ac in human cells. EMBO J. 28, 1878-1889 (2009).
22. Yuan, J., Pu, M., Zhang, Z. & Lou, Z. Histone H3-K56 acetylation is important for genomic stability in mammals. Cell Cycle 8, 1747-1753 (2009).
23. Uchida, S. et al. Stress-activated mitogen-activated protein kinases c-Jun NH2-terminal kinase and p38 target Cdc25B for degradation. Cancer Res. 69, 6438-6444 (2009).
24. Liu, Q. et al. Expression of cytoplasmic p16 and anion exchanger 1 is associated with the invasion and absence of lymph metastasis in gastric carcinoma. Mol. Med. Report 2, 169-174 (2009).
25. Iguchi, T. et al. Combined treatment of leukemia cells with vitamin K2 and 1alpha,25-dihydroxy vitamin D3 enhances monocytic differentiation along with becoming resistant to apoptosis by induction of cytoplasmic p21CIP1. Int. J. Oncol. 27, 893-900 (2005).
26. Shew, J. Y. et al. C-terminal truncation of the retinoblastoma gene product leads to functional inactivation. Proc. Natl Acad. Sci. USA 87, 6-10 (1990).
27. Harlow, E., Whyte, P., Franza, B. R. Jr. & Schley, C. Association of adenovirus early-region 1A proteins with cellular polypeptides. Mol. Cell. Biol. 6, 1579-1589 (1986). (Pubitemid 16089494)
28. Muraoka, M. et al. p300 gene alterations in colorectal and gastric carcinomas. Oncogene 12, 1565-1569 (1996). (Pubitemid 26132043)
29. Kishimoto, M. et al. Mutations and deletions of the CBP gene in human lung cancer. Clin. Cancer Res. 11, 512-519 (2005). (Pubitemid 40116874)
30. Bryan, E. J. et al. Mutation analysis of EP300 in colon, breast and ovarian carcinomas. Int. J. Cancer 102, 137-141 (2002). (Pubitemid 35168025)
31. Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730 (2005). (Pubitemid 41117277)
32. Courtois-Cox, S. et al. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10, 459-472 (2006). (Pubitemid 44872980)
33. Shamma, A. et al. Rb Regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation. Cancer Cell 15, 255-269 (2009).
34. Alimonti, A. et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J. Clin. Invest. 120, 681-693 (2010).
35. Hiratani, I. et al. Genome-wide dynamics of replication timing revealed by in vitro models of mouse embryogenesis. Genome Res. 20, 155-169 (2009).
36. Hiratani, I. et al. Global reorganization of replication domains during embryonic stem cell differentiation. PLoS Biol. 6, e245 (2008).
37. Hansen, R. S. et al. Sequencing newly replicated DNA reveals widespread plasticity in human replication timing. Proc. Natl Acad. Sci. USA 107, 139-144 (2009).
38. Hiratani, I. & Gilbert, D. M. Replication timing as an epigenetic mark. Epigenetics 4, 93-97 (2009).
39. Mikhailov, A., Shinohara, M. & Rieder, C. L. The p38-mediated stress-activated checkpoint. A rapid response system for delaying progression through antephase and entry into mitosis. Cell Cycle 4, 57-62 (2005). (Pubitemid 41038928)
40. Karlsson-Rosenthal, C. & Millar, J. B. Cdc25: Mechanisms of checkpoint inhibition and recovery. Trends Cell Biol. 16, 285-292 (2006). (Pubitemid 43868088)
41. Thomas, Y., Coux, O. & Baldin, V. betaTrCP-dependent degradation of CDC25B phosphatase at the metaphase-anaphase transition is a pre-requisite for correct mitotic exit. Cell Cycle 9, 4338-4350 (2010).
42. Zhang, J., Xu, F., Hashimshony, T., Keshet, I. & Cedar, H. Establishment of transcriptional competence in early and late S phase. Nature 420, 198-202 (2002). (Pubitemid 35340126)
43. Nardella, C., Clohessy, J. G., Alimonti, A. & Pandolfi, P. P. Pro-senescence therapy for cancer treatment. Nat. Rev. Cancer 11, 503-511 (2011).
44. Sherr, C. J. & McCormick, F. The RB and p53 pathways in cancer. Cancer Cell 2, 103-112 (2002). (Pubitemid 41039110)
45. Shehzad, A., Wahid, F. & Lee, Y. S. Curcumin in cancer chemoprevention: Molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch. Pharm. (Weinheim) 343, 489-499 (2010).
46. Dhillon, N. et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 14, 4491-4499 (2008).
47. Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363-9367 (1995).
48. Kuilman, T. et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133, 1019-1031 (2008). (Pubitemid 351787746)